SAVA - Cassava swings to Q1 profit as more patients finish simufilam phase 3 trials
2024-05-10 16:48:23 ET
More on Cassava Sciences
- Cassava Sciences: New Year, Same Game Of Smoke And Mirrors
- Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go?
- Cassava Sciences GAAP EPS of -$0.43 beats by $0.03
- Cassava Sciences raises over $125M from warrant distribution
- Seeking Alpha’s Quant Rating on Cassava Sciences